Baxalta Ventures

Baxalta Ventures

Baxalta Ventures

Learn about Baxaltas values, company leadership, and our passion for improving patient care.
Follow us
FinSMEs

Alexion To Acquire Syntimmune, for Up To $1.2 Billion

Health
$40,000,000 Venture capital (Series B)
FinSMEs , PE HUB , Xconomy , +1

OncoResponse Raises $40M in Series B Financing

Funding Health
PE HUB

| Apple Tree-backed Syntimmune appoints president and CEO

Strategy Health
Xconomy

Syntimmune Snares $50M to Test Autoimmune Drug in Two Rare Diseases

Health Science
$26,000,000 Venture capital (Series A)
VentureWire

The Daily Startup: Syntimmune Fights Autoimmune Diseases With New Funds

Funding
$26,000,000 Venture capital (Series A)
businesswire

Syntimmune Secures Second Tranche of $26 Million Series A Financing

Xconomy

NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree

Funding Health